



ABL1 (phospho Y134) polyclonal antibody

Catalog # PAB0396 Size 400 uL

Applications





Immunohistochemistry (Formalin/PFA-fixed paraffinembedded sections)

Formalin-fixed and paraffin-embedded human cancer tissue reacted with ABL1 (phospho Y134) polyclonal antibody (Cat # PAB0396) which was peroxidase-conjugated to the secondary antibody followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma.

Dot Blot (Peptide)

Dot blot analysis of ABL1 (phospho Y134) polyclonal antibody (Cat # PAB0396) on nitrocellulose membrane. 50 ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed.

Specification	
Product Description	Rabbit polyclonal antibody raised against synthetic phosphopeptide of ABL1.
Immunogen	Synthetic phosphopeptide (conjugated with KLH) corresponding to residues surrounding Y134 of human ABL1.
Host	Rabbit
Reactivity	Human
Form	Liquid
Purification	Protein G purification



Product Information

Recommend Usage	Immunohistochemistry (1:50-100) Dot Blot (1:500) The optimal working dilution should be determined by the end user.
Storage Buffer	In PBS (0.09% sodium azide)
Storage Instruction	Store at 4°C. For long term storage store at -20°C. Aliquot to avoid repeated freezing and thawing.
Note	This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which shoul d be handled by trained staff only.

Applications

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)

Formalin-fixed and paraffin-embedded human cancer tissue reacted with ABL1 (phospho Y134) polyclonal antibody (Cat # PAB0396) which was peroxidase-conjugated to the secondary antibody followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma.

Dot Blot (Peptide)

Dot blot analysis of ABL1 (phospho Y134) polyclonal antibody (Cat # PAB0396) on nitrocellulose membrane. 50 ng of Phosphopeptide or Non Phosphopeptide per dot were adsorbed.

Gene Info — ABL1	
Entrez GeneID	<u>25</u>
Protein Accession#	NP_005148;P00519
Gene Name	ABL1
Gene Alias	ABL, JTK7, bcr/abl, c-ABL, p150, v-abl
Gene Description	c-abl oncogene 1, receptor tyrosine kinase
Omim ID	189980
Gene Ontology	<u>Hyperlink</u>



Product Information

Gene Summary

The ABL1 protooncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has be en implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain n turns ABL1 into an oncogene. The t(9;22) translocation results in the head-to-tail fusion of the B CR (MIM:151410) and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC 2-mediated phosphorylation, suggesting a cell cycle function for ABL1. The ABL1 gene is expressed as either a 6- or 7-kb mRNA transcript, with alternatively spliced first exons spliced to the common exons 2-11. [provided by RefSeq

Other Designations

Abelson murine leukemia viral (v-abl) oncogene homolog 1|OTTHUMP00000022375|OTTHUMP0 0000022376|bcr/c-abl oncogene protein|proto-oncogene tyrosine-protein kinase ABL1|v-abl Abel son murine leukemia viral oncogene homolog 1

Publication Reference

 Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.

Barnes K, McIntosh E, Whetton AD, Daley GQ, Bentley J, Baldwin SA.

Oncogene 2005 May; 24(20):3257.

Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH:
 problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH.

Kim YR, Cho HI, Yoon SS, Park S, Kim BK, Lee YK, Chun H, Kim HC, Lee DS.

Genes, Chromosomes & Cancer 2005 May; 43(1):37.

 Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood 2004 Dec; 105(8):3303.

Pathway

- Axon guidance
- Cell cycle
- Chronic myeloid leukemia
- ErbB signaling pathway



- Neurotrophin signaling pathway
- Pathogenic Escherichia coli infection EHEC
- Pathways in cancer

Disease

- Adenocarcinoma
- Alzheimer disease
- Breast cancer
- Breast Neoplasms
- Cardiovascular Diseases
- Chronic Disease
- <u>Diabetes Complications</u>
- Esophageal Neoplasms
- Genetic Predisposition to Disease
- HIV Infections
- Leukemia
- Metabolic Syndrome X
- Neoplasms
- Osteoporosis
- Ovarian cancer
- Ovarian Neoplasms